Search clinical trials for: L2 childhood acute lymphoblastic leukemia

Total 31840 results

Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)

Hepatocellular Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

Metastatic Castration-resistant Prostate Cancer
Merck Sharp & Dohme LLC

Completed

Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)

Non-Small-Cell Lung Cancer
Merck Sharp & Dohme LLC

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Israel, United States, Taiwan, Hong Kong, Korea, Republic of, Switzerland, Costa Rica
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, New Zealand
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Neoplasm Metastasis
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)

Bladder Cancer

Canada, New Zealand, Germany, Australia, United States, Poland, Spain, Chile, Sweden, France, Italy
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

Advanced or Metastatic Solid Tumors

Canada, Switzerland, United States
Merck Sharp & Dohme LLC

Recruiting

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Lung Neoplasms | Non-Small-Cell Lung Carcinoma

United States, Brazil, Canada, Chile, China, Guatemala, Hong Kong, Hungary, Japan, Korea, Republic of, Malaysia, Mexico, Peru, Russian Federation, South Africa, Taiwan, Thailand, Ukraine, Romania, Dominican Republic, Philippines, ... and more
Merck Sharp & Dohme LLC
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Endometrial Neoplasms

Australia, United States, Germany, Israel, Korea, Republic of, Poland, Turkey, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, Hungary, Ireland, Italy, Japan, Netherlands, New Zealand, Norway, Russian Federation, Spain, Swed... and more
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

Mesothelioma

Japan
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network for Gynaecological Oncological...

Active, not recruiting

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Endometrial Neoplasms

United States, Argentina, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Norway, Poland, Russian Federation, Spain, Sweden, Taiwan, T... and more
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

Urothelial Carcinoma Associated 1 RNA, Human
Merck Sharp & Dohme LLC
Novartis Pharmaceuticals

Completed

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

Melanoma | Solid Tumors
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Colorectal Cancer

United States, Australia, Canada, Chile, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Malaysia, Norway, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Colorectal Cancer

China
Merck Sharp & Dohme LLC
Astellas Pharma Inc; Seagen Inc.

Active, not recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)

Bladder Cancer

Hungary, United States, China, Argentina, Australia, Bulgaria, Canada, Colombia, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Philippines, Poland, Portugal, Romania, Russian Federation, Singapo... and more
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
Merck Sharp & Dohme LLC

Completed

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

Esophageal Neoplasms

Taiwan, China, United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Denmark, France, Germany, Guatemala, Hong Kong, Japan, Korea, Republic of, Malaysia, Peru, Romania, Russian Federation, South Africa, S... and more
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Prostatic Neoplasms

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Urothelial Cancer
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Triple Negative Breast Neoplasms

Colombia, United States, Canada, Chile, France, Germany, Hungary, Ireland, Japan, Korea, Republic of, Poland, Spain, Taiwan, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Non-Small Cell Lung Cancer

Poland, United States, Brazil, France, Guatemala, Hungary, Japan, Korea, Republic of, Peru, Romania, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Merkel Cell Carcinoma

United States, Australia, Canada, France, Italy, New Zealand, Spain, Sweden
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)

Richter Syndrome | Mediastinal Large B-cell Lymphoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)

Esophageal Carcinoma | Esophagogastric Junction Carcinoma
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) (KEYNOTE-C11)

Classical Hodgkin Lymphoma

Poland, United States, Australia, Canada, Chile, France, Israel, Italy, Russian Federation, Spain, Turkey
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Small Cell Lung Cancer (SCLC)

United States, Australia, Canada, Chile, France, Germany, Hungary, Ireland, Israel, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Switzerland, Taiwan, Turkey, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

Carcinoma, Hepatocellular

United States, Australia, Canada, Chile, China, Colombia, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Spain, Taiwan, Thailand, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Withdrawn

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Esophageal Neoplasms

China
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Esophageal Squamous Cell Carcinoma

Japan, Korea, Republic of, Taiwan, China, Italy, Switzerland, Brazil, Germany, Singapore, Turkey, Thailand, Chile, Norway
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Esophageal Squamous Cell Carcinoma (ESCC)

Japan, Italy, Brazil, Chile, France, Germany, Korea, Republic of, Norway, Singapore, Switzerland, Taiwan, Thailand, Turkey
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Carcinoma, Squamous Cell

Ukraine, United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Mexico, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Spain, United Kingdom
Merck Sharp & Dohme LLC
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

Uterine Cervical Neoplasms

Canada, United States, Australia, Austria, Belgium, Brazil, Chile, China, Colombia, Czechia, France, Germany, Greece, Guatemala, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Norway, Peru, Russian Federation, Spain, Sweden, ... and more
Merck Sharp & Dohme LLC

Completed

Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782)

Non-Small Cell Lung Cancer

United States, Canada, Hungary, Israel, Spain
Merck Sharp & Dohme LLC
European Organisation for Research and Treatment of Cancer

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

Melanoma
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia

Leukemia

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Advanced/Metastatic Melanoma

United States, Australia, Chile, France, Germany, Israel, Italy, Korea, Republic of, Norway, South Africa, Spain
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

Sarcoma | Kidney Cancer | Unspecified Childhood Solid Tumor, Protocol Specific | Leukemia | Ovarian Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Liver Cancer | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

Carcinoma, Hepatocellular

Korea, Republic of, China, Hong Kong, Malaysia, Taiwan
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Advanced Hepatocellular Carcinoma

United States, China, Italy, Japan, Korea, Republic of, Poland, Spain, Switzerland, Taiwan
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Gastric Adenocarcinoma

3

Subscribe